KPW
ATRA icon

Kore Private Wealth’s Atara Biotherapeutics ATRA Stock Holding History

Kore Private Wealth’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-40
Closed -$40K – 270
2019
Q1 		$40K Hold
40
– – 0.01% 417
2018
Q4 		$35K Buy
+40
New +$37.1K 0.01% 420

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Kore Private Wealth's ATRA Position: Q2 2019 in Review

Kore Private Wealth sold out of Atara Biotherapeutics (ATRA) in Q2 2019, closing a stake of 40 shares — an estimated $40K sold.

Kore Private Wealth first reported a position in ATRA in Q4 2018 and held it in 2 quarters. The position peaked at $40K in Q1 2019. 116 funds tracked by Wall St. Rank hold ATRA as of Q2 2019.

  • Kore Private Wealth reported no remaining Atara Biotherapeutics position as of Q2 2019 after selling out during the quarter.
  • Kore Private Wealth sold 40 Atara Biotherapeutics shares in Q2 2019, an estimated $40K.
  • Kore Private Wealth first reported a position in Atara Biotherapeutics in Q4 2018 and held it in 2 quarters.
  • Kore Private Wealth's Atara Biotherapeutics position peaked at $40K in Q1 2019.
  • 116 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2019.

Based on Kore Private Wealth's 13F filing for Q2 2019, filed 14 Aug 2019.